21.42 USD
+0.06 (+0.28%)
21.42 USD
0 (0%)
Taking everything into account, AVDL scores 5 out of 10 in our fundamental rating. AVDL was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for AVDL as it has an excellent financial health rating, but there are worries on the profitability. AVDL is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
AVDL had negative earnings in the past year.
AVDL had a positive operating cash flow in the past year.
In the past 5 years AVDL reported 4 times negative net income.
AVDL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -0.14%, AVDL is in the better half of the industry, outperforming 76.44% of the companies in the same industry.
AVDL has a Return On Equity of -0.28%. This is in the better half of the industry: AVDL outperforms 78.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.28% | ||
| ROIC | N/A |
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AVDL has a Gross Margin of 91.09%. This is amongst the best in the industry. AVDL outperforms 92.67% of its industry peers.
AVDL's Gross Margin has improved in the last couple of years.
AVDL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
2. Health
2.1 Basic Checks
AVDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
AVDL has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AVDL has more shares outstanding
Compared to 1 year ago, AVDL has a worse debt to assets ratio.
2.2 Solvency
AVDL has an Altman-Z score of 7.75. This indicates that AVDL is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of AVDL (7.75) is better than 80.63% of its industry peers.
The Debt to FCF ratio of AVDL is 1.80, which is an excellent value as it means it would take AVDL, only 1.80 years of fcf income to pay off all of its debts.
AVDL has a Debt to FCF ratio of 1.80. This is amongst the best in the industry. AVDL outperforms 94.76% of its industry peers.
AVDL has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
AVDL's Debt to Equity ratio of 0.35 is in line compared to the rest of the industry. AVDL outperforms 40.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.8 | ||
| Altman-Z | 7.75 |
ROIC/WACCN/A
WACC7.73%
2.3 Liquidity
AVDL has a Current Ratio of 2.76. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
AVDL has a Current ratio of 2.76. This is comparable to the rest of the industry: AVDL outperforms 48.69% of its industry peers.
AVDL has a Quick Ratio of 2.37. This indicates that AVDL is financially healthy and has no problem in meeting its short term obligations.
AVDL has a Quick ratio (2.37) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.37 |
3. Growth
3.1 Past
AVDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.00%, which is quite impressive.
AVDL shows a strong growth in Revenue. In the last year, the Revenue has grown by 79.88%.
The Revenue has been growing by 23.35% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%
3.2 Future
AVDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.00% yearly.
The Revenue is expected to grow by 25.12% on average over the next years. This is a very strong growth
EPS Next Y138.39%
EPS Next 2Y89.39%
EPS Next 3Y64.19%
EPS Next 5Y43%
Revenue Next Year62.59%
Revenue Next 2Y45.88%
Revenue Next 3Y39.03%
Revenue Next 5Y25.12%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Forward Earnings ratio of 25.96, the valuation of AVDL can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AVDL indicates a somewhat cheap valuation: AVDL is cheaper than 73.30% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.78, AVDL is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.96 |
4.2 Price Multiples
75.92% of the companies in the same industry are more expensive than AVDL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 100.25 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AVDL's earnings are expected to grow with 64.19% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y89.39%
EPS Next 3Y64.19%
5. Dividend
5.1 Amount
AVDL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
21.42
+0.06 (+0.28%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners90.53%
Inst Owner Change-11.9%
Ins Owners4.79%
Ins Owner Change1.1%
Market Cap1.94B
Revenue(TTM)248.52M
Net Income(TTM)-278.00K
Analysts70
Price Target21.48 (0.28%)
Short Float %7.72%
Short Ratio2.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)79.03%
Min EPS beat(2)-100%
Max EPS beat(2)258.07%
EPS beat(4)2
Avg EPS beat(4)42.28%
Min EPS beat(4)-100%
Max EPS beat(4)258.07%
EPS beat(8)4
Avg EPS beat(8)22.06%
EPS beat(12)4
Avg EPS beat(12)-2.88%
EPS beat(16)5
Avg EPS beat(16)-12.25%
Revenue beat(2)2
Avg Revenue beat(2)5.92%
Min Revenue beat(2)3.23%
Max Revenue beat(2)8.61%
Revenue beat(4)3
Avg Revenue beat(4)3.03%
Min Revenue beat(4)-1.22%
Max Revenue beat(4)8.61%
Revenue beat(8)7
Avg Revenue beat(8)3.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.29%
PT rev (3m)4.24%
EPS NQ rev (1m)4.63%
EPS NQ rev (3m)-20.73%
EPS NY rev (1m)-12.53%
EPS NY rev (3m)-17.47%
Revenue NQ rev (1m)0.81%
Revenue NQ rev (3m)0.21%
Revenue NY rev (1m)0.77%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 25.96 | ||
| P/S | 7.81 | ||
| P/FCF | 100.25 | ||
| P/OCF | 56.17 | ||
| P/B | 19.75 | ||
| P/tB | 23.84 | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)0.83
Fwd EY3.85%
FCF(TTM)0.21
FCFY1%
OCF(TTM)0.38
OCFY1.78%
SpS2.74
BVpS1.08
TBVpS0.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.14% | ||
| ROE | -0.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.09% | ||
| FCFM | 7.79% |
ROA(3y)-76.86%
ROA(5y)-51.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.73%
F-Score4
Asset Turnover1.25
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.8 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.76 | ||
| Quick Ratio | 2.37 | ||
| Altman-Z | 7.75 |
F-Score4
WACC7.73%
ROIC/WACCN/A
Cap/Depr(3y)15.99%
Cap/Depr(5y)11.39%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y138.39%
EPS Next 2Y89.39%
EPS Next 3Y64.19%
EPS Next 5Y43%
Revenue 1Y (TTM)79.88%
Revenue growth 3YN/A
Revenue growth 5Y23.35%
Sales Q2Q%54.86%
Revenue Next Year62.59%
Revenue Next 2Y45.88%
Revenue Next 3Y39.03%
Revenue Next 5Y25.12%
EBIT growth 1Y92.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year158.03%
EBIT Next 3Y69.86%
EBIT Next 5Y44.46%
FCF growth 1Y116.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y129.82%
OCF growth 3YN/A
OCF growth 5YN/A
AVADEL PHARMACEUTICALS / AVDL FAQ
Can you provide the ChartMill fundamental rating for AVADEL PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 5 / 10 to AVDL.
Can you provide the valuation status for AVADEL PHARMACEUTICALS?
ChartMill assigns a valuation rating of 4 / 10 to AVADEL PHARMACEUTICALS (AVDL). This can be considered as Fairly Valued.
How profitable is AVADEL PHARMACEUTICALS (AVDL) stock?
AVADEL PHARMACEUTICALS (AVDL) has a profitability rating of 3 / 10.
What is the expected EPS growth for AVADEL PHARMACEUTICALS (AVDL) stock?
The Earnings per Share (EPS) of AVADEL PHARMACEUTICALS (AVDL) is expected to grow by 138.39% in the next year.